Pascal Soriot, the still-new chief executive officer of AstraZeneca, said Tuesday that he was changing the leadership lineup below his spot on the organizational chart.
When the music stopped, there were no chairs for Martin Mackay, president of research and development, and Tony Zook, executive vice president, global commercial. Their roles were eliminated and, as the company said in its statement, "Martin Mackay and Tony Zook will leave the company at the end of January."
AstraZeneca is based in the United Kingdom, but has one of three regional headquarters in Wilmington and a second facility in Newark, Del. The company is trying to adjust to the loss of revenue from high-profit drugs that now face generic competition.
“This new senior executive team structure, that draws heavily from the leadership talent within the company, enables us to bring an even sharper management focus to key pipeline assets, key brands and key markets, and helps us further accelerate decision-making,” Soriot said in a statement.